The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)
Abstract
To learn about the carboxy-terminal extent of amyloid beta-protein (A beta) composition of senile plaques (SPs) in the brain affected with Alzheimer's disease (AD), we employed two end-specific monoclonal antibodies as immunocytochemical probes: one is specific for A beta 40, the carboxyl terminus of A beta 1-40, while the other is specific for A beta 42(43). In the AD cortex, all SPs that were labeled with an authentic antibody were A beta 42(43) positive, while only one-third of which, on the average, were A beta 40 positive. There was a strong correlation between A beta 40 positivity and mature plaques. Two familial AD cortices with the mutation of beta-amyloid protein precursor 717 (beta APP717) (Val to Ile) showed a remarkable predominance of A beta 42(43)-positive, A beta 40-negative plaques. Diffuse plaques, representing the earliest stage of A beta deposition, were exclusively positive for A beta 42(43), but completely negative for A beta 40.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These observations indicate that Aps ending at Ap42(43), which are a minor component of the Ap in human cerebrospinal fluid and plasma, are critically important in AD where they deposit selectively in plaques of all kinds.”
From Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain (1995) · cites this paper as [21]
In the citing paper
“The immunocytochemical results shown here and in a recent report by Iwatsubo et al. (21) demonstrate that BC-05 intensely stains all types of senile plaques, that vessels are stained by both BC-OS and BA-27, and that BA-27 stains plaques poorly, in many cases only faintly staining occasional cored plaques (Fig. 3).”
From Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain (1995) · cites this paper as [21]
In the citing paper
“From studies of trisomy 21 brains (Iwatsubo et al., 1994), it is generally believed that, in human AD, A deposition begins with the formation of diffuse plaques.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Iwatsubo et al., 1994
In the citing paper
“there is good evidence that A1-42 is deposited early and selectively in senile plaques (Iwatsubo et al., 1994).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Iwatsubo et al., 1994
In the citing paper
“In contrast, Aβ40, the major Aβ peptide secreted by cells, appears to be the predominant species deposited in the amyloid deposits in the cerebral vasculature (congophillic angiopathy, CAA) (Gravina et al., 1995; Iwatsubo et al., 1994).”
From Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice (2005) · cites this paper as Iwatsubo et al., 1994
In the citing paper
“These data provide definitive in vivo confirmation of predictions inferred from (1) in vitro studies of Aβ aggregation, (2) effects of PS and certain APP mutations on Aβ production and deposition, and (3) analyses of Aβ peptides in the human AD brain (Gravina et al., 1995; Iwatsubo et al., 1994).”
From Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice (2005) · cites this paper as Iwatsubo et al., 1994
In the citing paper
“Indeed, Aβ42 is the main component of amyloid plaques and is shown to be neurotoxic [30].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [30]
In the citing paper
“the slightly longer Aβ42 species that is specifically linked with FAD is also the first Aβ species deposited in cerebral plaques [82].”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [82]
In the citing paper
“The subsequent development of antibodies directed at the free C-terminal ends of Aβ40 or Aβ42 [82] led to the ability to differentiate Aβ from APP labeling”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [82]
Citations
Cites
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Groen, T. V., Liu, L., Ikonen, S., & Kadish, I. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00215-x · Cited by 35
The relationship between αB‐crystallin and neurofibrillary tangles in Alzheimer's disease
Mao, J., Katayama, S., Watanabe, C., Harada, Y., Noda, K., Yamamura, Y., & Nakamura, S. (2001) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2001.00310.x · Cited by 35
Ishii, K., Ii, K., Hasegawa, T., Shoji, S., Doi, A., & Mori, H. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00347-9 · Cited by 44
Steroids as γ‐secretase modulators
Jung, J. I., Ladd, T. B., Kukar, T. L., Price, A. R., Moore, B. D., Koo, E. H., Golde, T. E., & Felsenstein, K. M. (2013) · The FASEB Journal · doi:10.1096/fj.12-225649 · Cited by 35
Chen, G., Liu, C., Meng, G., Zhang, C., Chen, F., Tang, S., Hong, H., & Zhang, C. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13056 · Cited by 34
Fanni, A. M., Monge, F. A., Lin, C., Thapa, A., Bhaskar, K., Whitten, D. G., & Chi, E. Y. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00719 · Cited by 35
Du, F., Zhou, L., Jiao, Y., Bai, S., Wang, L., Ma, J., & Fu, X. (2019) · Molecules · doi:10.3390/molecules24040729 · Cited by 34
Habiba, U., Merlin, S., Lim, J. K. H., Wong, V. H. Y., Nguyen, C. T. O., Morley, J. W., Bui, B. V., & Tayebi, M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191346 · Cited by 33
A History of Senile Plaques: From Alzheimer to Amyloid Imaging
Beach, T. G. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac030 · Cited by 37
The Mitochondrial Secret(ase) of Alzheimer's Disease
Young, K. J., & Bennett, J. P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100360 · Cited by 34
Karlnoski, R., Rosenthal, A., Kobayashi, D. T., Pons, J., Alamed, J., Mercer, M., Li, Q., Gordon, M. N., Gottschall, P. E., & Morgan, D. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4560-08.2009 · Cited by 34
Qu, B. X., Lambracht‐Washington, D., Fu, M., Eagar, T. N., Stüve, O., & Rosenberg, R. N. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.05.054 · Cited by 34
A role for p53 in the β-amyloid-mediated regulation of the lysosomal system
Fogarty, M. P., McCormack, R. M., Noonan, J., Murphy, D. B., Gowran, A., & Campbell, V. A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.09.018 · Cited by 35
Cavani, S., Tamaoka, A., Moretti, A., Marinelli, L., Angelini, G., Stefano, S. D., Piombo, G., Cazzulo, V., Matsuno, S., Shoji, S., et al. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20001127)95:3 · Cited by 33
Intraneuronal amyloid β42 enhanced by heating but counteracted by formic acid
Ohyagi, Y., Tsuruta, Y., Motomura, K., Miyoshi, K., Kikuchi, H., Iwaki, T., Taniwaki, T., & Kira, J. (2006) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2006.06.010 · Cited by 36
Neurohormonal Signaling Pathways and the Regulation of Alzheimer β-Amyloid Precursor Metabolism
Gandy, S. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(99)00166-6 · Cited by 32
Secretases as therapeutic targets for the treatment of Alzheimer's disease
Dominguez, D. I., Strooper, B. D., & Annaert, W. G. (2001) · Amyloid · doi:10.3109/13506120109007356 · Cited by 35
Cdc42GAP deficiency contributes to the Alzheimer’s disease phenotype
Zhu, M., Xiao, B., Xue, T., Qin, S., Ding, J., Wu, Y. H., Tang, Q., Huang, M., Zhao, N., Ye, Y., et al. (2023) · Brain · doi:10.1093/brain/awad184 · Cited by 32
Tsigelny, I. F., Sharikov, Y., Kouznetsova, V. L., Greenberg, J. P., Wrasidlo, W., Gonzalez, T., Desplats, P., Michael, S. E., Trejo, M., Overk, C., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131589 · Cited by 33
Jung, J. I., Premraj, S., Cruz, P. E., Ladd, T. B., Kwak, Y., Koo, E. H., Felsenstein, K. M., Golde, T. E., & Ran, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111553 · Cited by 33
Thomas, A. J., Morris, C. M., Ferrier, I. N., & Kalaria, R. N. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06353.x · Cited by 34
Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains
Pirttilä, T., Soininen, H. S., Mehta, P. D., Heinonen, O., Lehtimäki, T. J., Bogdanović, N., Paljärvi, L., Kim, K. S., Kosunen, O., Winblad, B. G., et al. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(96)00204-7 · Cited by 33
Savage, M. J., Kawooya, J. K., Pinsker, L. R., Emmons, T. L., Mistretta, S., Siman, R. G., & Greenberg, B. (1995) · Amyloid · doi:10.3109/13506129508999005 · Cited by 33
The Alzheimer's disease sphinx: a riddle with plaques and tangles.
Kosik, K. S. (1994) · The Journal of Cell Biology · doi:10.1083/jcb.127.6.1501 · Cited by 33
Chambers, J. K., Kuribayashi, H., Ikeda, S.-I., & Une, Y. (2010) · Amyloid · doi:10.3109/13506129.2010.483119 · Cited by 32
RETRACTED ARTICLE: Gantenerumab for the treatment of Alzheimer's disease
Delrieu, J., Ousset, P., & Vellas, B. J. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.688022 · Cited by 32
RetractedInterpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β
Toyn, J. H., & Ahlijanian, M. K. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt244 · Cited by 31
Aissouq, A. E., Toufik, H., Stitou, M., Ouammou, A., & Lamchouri, F. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09939-8 · Cited by 32
Alzheimer’s Aβ42 and Aβ40 form mixed oligomers with direct molecular interactions
Gu, L., & Guo, Z. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.092 · Cited by 32
Du, F., Zhao, H., Yao, M., Yang, Y., Jiao, J., & Li, C. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114850 · Cited by 32
Zhou, Y., Jiang, C., Zhang, Y., Liang, Z. T., Liu, W., Wang, L., Luo, C., Zhong, T., Sun, Y. E., Zhao, L., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1000584 · Cited by 32
Genetic and biochemical markers for Alzheimer's disease: recent developments
Mulder, C., Scheltens, P., Visser, J. J., van Kamp, G. J., & Schutgens, R. B. H. (2000) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/0004563001899898 · Cited by 32
Mosser, S., Alattia, J., Dimitrov, M. I., Matz, A., Pascual, J., Schneider, B. L., & Fraering, P. C. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu449 · Cited by 33
Akiyama, H., Mori, H., Sahara, N., Kondo, H., Ikeda, K., Nishimura, T., Oda, T., & McGeer, P. L. (1997) · Neurochemical Research · doi:10.1023/a:1021910729963 · Cited by 32
Bornebroek, M., Haan, J., & Roos, R. A. C. (1999) · Amyloid · doi:10.3109/13506129909007331 · Cited by 32
Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer’s disease
Gandy, S. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00125-2 · Cited by 32
Insights into Aβ and Presenilin from a Canine Model of Human Brain Aging
Head, E., & Torp, R. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0476 · Cited by 32
Secreted Aβ Does Not Mediate Neurotoxicity by Antibody-Stimulated Amyloid Precursor Protein
Sudo, H., Hashimoto, Y., Niikura, T., Shao, Z., Yasukawa, T., Ito, Y., Yamada, M., Hata, M., Hiraki, T., Kawasumi, M., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4604 · Cited by 32
A critical appraisal of blood-based biomarkers for Alzheimer’s disease
Lista, S., Mapstone, M. E., Caraci, F., Emanuele, E., López‐Ortiz, S., Martín-Hernández, J., Triaca, V., Imbimbo, C., Gabelle, A., Mielke, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102290 · Cited by 30
Sakai‐Kato, K., Naito, M., & Utsunomiya‐Tate, N. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.014 · Cited by 32
Moll, L., & Schubert, M. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/384094 · Cited by 31
Covalent modifier-type aggregation inhibitor of amyloid-β based on a cyclo-KLVFF motif
Kino, R., Araya, T., Arai, T., Sohma, Y., & Kanai, M. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.027 · Cited by 32
Hadar, A., Milanesi, E., Squassina, A., Niola, P., Chillotti, C., Pasmanik-Chor, M., Yaron, O., Pavel Martasek, E., Rehavi, M., Weissglas‐Volkov, D., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.179 · Cited by 31
A near atomic-scale view at the composition of amyloid-beta fibrils by atom probe tomography
Rusitzka, K. A. K., Stephenson, L. T., Szczepaniak, A., Gremer, L., Raabe, D., Willbold, D., & Gault, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-36110-y · Cited by 30
Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors
Przybyłowska, M., Dzierzbicka, K., Kowalski, S., Chmielewska, K., & Inkielewicz‐Stępniak, I. (2020) · Current Neuropharmacology · doi:10.2174/1570159x19666201218103434 · Cited by 31
Therapeutic role of curcumin in oxidative DNA damage caused by formaldehyde
Çiftçi, G., Aksoy, A., Çenesiz, S., Söğüt, M. Ü., Yarım, G. F., Nisbet, C., Güvenç, D., & Ertekin, A. (2015) · Microscopy Research and Technique · doi:10.1002/jemt.22485 · Cited by 31
Biomarkers in Alzheimer’s Disease
Riverol, M., & López, O. L. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00046 · Cited by 33
Postupna, N. O., Keene, C. D., Latimer, C. S., Sherfield, E., Gelder, R. D. V., Ojemann, J. G., Montine, T. J., & Darvas, M. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.103 · Cited by 31
Irie, K., Yanagita, R. C., & Nakagawa, Y. (2010) · Medicinal Research Reviews · doi:10.1002/med.20220 · Cited by 31
Chen, T., Hung, H., Wang, D., & Chen, S.-S. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq114 · Cited by 31
Noda-Saita, K., Terai, K., Iwai, A., Tsukamoto, M., Shitaka, Y., Kawabata, S., Okada, M., & Yamaguchi, T. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0907-2 · Cited by 30
Iizuka, T., Shoji, M., Harigaya, Y., Kawarabayashi, T., Watanabe, M., Kanai, M., & Hirai, S. (1995) · Brain Research · doi:10.1016/0006-8993(95)01163-2 · Cited by 33
Nakamura, S., Tamaoka, A., Sawamura, N., Kiatipattanasakul, W., Nakayama, H., Shoji, S., Yoshikawa, Y., & Doi, K. (1997) · Acta Neuropathologica · doi:10.1007/s004010050714 · Cited by 31
Yamaguchi, H., Sugihara, S., Ishiguro, K., Takashima, A., & Hirai, S. (1995) · Amyloid · doi:10.3109/13506129509031882 · Cited by 31
Andersson, E., Lindblom, N., Janelidze, S., Salvadó, G., Gkanatsiou, E., Söderberg, L., Möller, C., Lannfelt, L., Ge, J., Hanrieder, J., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00810-8 · Cited by 38
Use of Biomarkers in Clinical Trials of Alzheimer Disease
Wu, L., Rosa‐Neto, P., & Gauthier, S. G. (2011) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256467 · Cited by 32
Enhanced Antigen Retrieval of Amyloid β Immunohistochemistry
Kai, H., Shin, R., Ogino, K., Hatsuta, H., Murayama, S., & Kitamoto, T. (2012) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155412456379 · Cited by 30
Michno, W., Wehrli, P. M., Meier, S. R., Sehlin, D., Syvänen, S., Zetterberg, H., Blennow, K., & Hanrieder, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14888 · Cited by 29
Citrullination of Amyloid-β Peptides in Alzheimer’s Disease
Mukherjee, S., Perez, K. A., Dubois, C., Nisbet, R. M., Li, Q., Varghese, S., Jin, L., Birchall, I. E., Streltsov, V. A., Vella, L. J., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00474 · Cited by 30
Perez, F. P., Bose, D., Maloney, B., Nho, K. T., Shah, K., & Lahiri, D. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131544 · Cited by 31
Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease
Pivtoraiko, V. N., Abrahamson, E. E., Leurgans, S. E., DeKosky, S. T., Mufson, E. J., & Ikonomović, M. D. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.021 · Cited by 32
Fraering, P. C. (2007) · Current Genomics · doi:10.2174/138920207783769521 · Cited by 30
Immunohistochemical investigation of amyloid beta-protein (Abeta) in the brain of aged cats.
Brellou, G. D., Vlemmas, I., Lekkas, S., & Papaioannou, N. G. (2005) · PubMed · doi:10.14670/hh-20.725 · Cited by 30
Kowa, H., Sakakura, T., Matsuura, Y., Wakabayashi, T., Mann, D. M. A., Duff, K., Tsuji, S., Hashimoto, T., & Iwatsubo, T. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63295-6 · Cited by 34
Self-citationYasuda, M. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.2.220 · Cited by 30
Serizawa, S., CHAMBERS, J. K., & Une, Y. (2011) · Veterinary Pathology · doi:10.1177/0300985811410719 · Cited by 32
Mann, Brown, Owen, Baba, & Iwatsubo, T. (1998) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1998.00112.x · Cited by 29
Self-citationKadoyama, K., Takahashi, Y., Higashida, H., Tanabe, T., & Yoshimoto, T. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4357 · Cited by 30
Association study of three polymorphisms of TGF-beta1 gene with Alzheimer's disease
Goumidi, L. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.1.62 · Cited by 30
Tolnay, M., Calhoun, Pham, Egensperger, & Probst (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00175.x · Cited by 30
Cellular and molecular basis of beta-amyloid precursor protein metabolism
Xu, H. (1998) · Frontiers in bioscience · doi:10.2741/a283 · Cited by 30
Interactions of amyloid-β peptides on lipid bilayer studied by single molecule imaging and tracking
Chang, C., Edwald, E., Veatch, S. L., Steel, D. G., & Gafni, A. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.03.017 · Cited by 31
Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization
Jäkel, L., Boche, D., Nicoll, J. A. R., & Verbeek, M. M. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0791-6 · Cited by 29
Enzlein, T., Cordes, J., Munteanu, B., Michno, W., Serneels, L., Strooper, B. D., Hanrieder, J., Ivo Wolf, A., Chávez‐Gutiérrez, L., & Hopf, C. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02585 · Cited by 28
Contribution of the γ-Secretase Subunits to the Formation of Catalytic Pore of Presenilin 1 Protein
Takeo, K., Watanabe, N., Tomita, T., & Iwatsubo, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.336347 · Cited by 28
Self-citationEffect of Melatonin and Melatonylvalpromide on β-amyloid and Neurofilaments in N2a Cells
Wang, X., Zhang, Y.-C., Chatterjie, N., Grundke, I., Iqbal, K., & Wang, J. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9563-y · Cited by 29
Härtig, W., Goldhammer, S., Bauer, U. U. I., Wegner, F., Wirths, O., Bayer, T. A., & Grosche, J. (2010) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2010.03.006 · Cited by 29
Jongbloed, W., Kester, M. I., van der Flier, W. M., Veerhuis, R., Scheltens, P., Blankenstein, M. A., & Teunissen, C. E. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.01.004 · Cited by 29
Does β-amyloid plaque formation cause structural injury to neuronal processes?
Woodhouse, A., West, A. K., Chuckowree, J. A., Vickers, J. C., & Dickson, T. C. (2005) · Neurotoxicity Research · doi:10.1007/bf03033772 · Cited by 30
Chu, T., Tran, T., Yang, F., Beech, W. K., Cole, G. M., & Frautschy, S. A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01161-2 · Cited by 29
[Plasma beta-endorphin and stress hormones in stress and adaptation].
Lishmanov, I. B., Trifonova, Z. V., Tsibin, A. N., Maslova, L. V., & Dement'eva, L. A. (1987) · PubMed · Cited by 29
Strazielle, C., Sturchler, C., Staufenbiel, M., & Lalonde, R. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00037-x · Cited by 31
Pritchard, A. L., Harris, J. M., Pritchard, C. W., Clair, D. S., Lemmon, H. A., Lambert, J., Chartier‐Harlin, M., Hayes, A., Thaker, U., Iwatsubo, T., et al. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.03.016 · Cited by 29
Self-citationAsami-Odaka, A., Obayashi-Adachi, Y., Matsumoto, Y., Takahashi, H., Fukumoto, H., Horiguchi, T., Suzuki, N., & Shoji, M. (2005) · Neurodegenerative Diseases · doi:10.1159/000086429 · Cited by 29
Self-citationTransgenic Mouse Models of Alzheimer's Disease and Amyotrophic Lateral Sclerosis
Borchelt, D., Wong, P. C., Sisodia, S. S., & Price, D. L. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00198.x · Cited by 29
Transgenic models of neurodegenerative diseases
Lee, M. K., Borchelt, D., Wong, P. C., Sisodia, S. S., & Price, D. L. (1996) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(96)80099-7 · Cited by 29
O’Toole, M. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1531 · Cited by 29
Association of CSF apolipoprotein E, Aβ42 and cognition in Alzheimer’s disease
Riemenschneider, M. J., Schmolke, M., Lautenschlager, N. T., Vanderstichele, H., Vanmechelen, E., Guder, W. G., & Kurz, A. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00272-x · Cited by 29
Pait, M. C., Kaye, S. D., Su, Y., Kumar, A., Singh, S., Gironda, S. C., Vincent, S., Anwar, M., Carroll, C. M., Snipes, J. A., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12398 · Cited by 29
Cai, T., Yonaga, M., & Tomita, T. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1628-17.2017 · Cited by 28
Wang, Y., Sun, Y., Luo, Y., Peng, D., Li, X., Yang, B., Wang, Q., & Kuang, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.700587 · Cited by 29
α-synuclein-assisted oligomerization of β-amyloid (1–42)
Chau, E., & Kim, J. R. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109120 · Cited by 30
Do, H. N., Devkota, S., Bhattarai, A., Wolfe, M. S., & Miao, Y. (2023) · Communications Biology · doi:10.1038/s42003-023-04539-1 · Cited by 27
Shanthi, K. B., Krishnan, S., & Rani, P. (2015) · SAGE Open Medicine · doi:10.1177/2050312115598250 · Cited by 29
Chang, C.-C., Althaus, J. C., Carruthers, C. J. L., Sutton, M. A., Steel, D. G., & Gafni, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082139 · Cited by 28
Meißner, J. N., Bouter, Y., & Bayer, T. A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142868 · Cited by 16
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Khan (2000) · doi:10.1002/1531-8249(200008)48:2
Nakagawa (1999) · doi:10.1002/(sici)1096-9861(19990830)411:3
Batardiere (1998) · doi:10.1002/(sici)1096-9861(19980713)396:4
Metadata
- Authors
- Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y.
- Affiliations
- Takeda (Japan) (JP)
- The University of Tokyo (JP)
- University of Tsukuba (JP)
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 1994-07
- Volume
- 13
- Issue
- 1
- Pages
- 45-53
- ISSN
- 0896-6273 (ISSN-L)
- OpenAlex
- W1991435932
- Cited by
- 1,774
- References
- 41
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 53 · 2023: 49 · 2022: 49 · 2021: 55 · 2020: 68 · 2019: 49 · 2018: 41 · 2017: 49 · 2016: 52 · 2015: 45 · 2014: 68 · 2013: 69 · 2012: 66
- FWCI
- 35.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, Aβ40, amyloid plaques, Alzheimer's disease, familial Alzheimer's disease, plaque maturation, diffuse plaques, immunocytochemistry
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Antibodies, Monoclonal, Brain, Cerebral Cortex, Female, Humans, Immunoenzyme Techniques, Male, Middle Aged, Mutation, Peptide Fragments, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
